Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | BCHE | P06276 | 4/20 | 0.65 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fagaridine SCHEMBL29369428 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL108986 | 0.91 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL6961260 | 0.90 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL9547964 | 0.90 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8711761 | 0.90 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8310818 | 0.85 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8310820 | 0.85 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL6402891 | 0.85 | ALDH1A1 (0.68) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL543021 | 0.80 | BAD (0.56) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| SCHEMBL29670768 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | ALDH1A1 2608/4885MAPT 4137/4885SMN1; SMN2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.